Design and development of synthetic peptide vaccines: past, present and future.
Synthetic peptide vaccines aiming at the induction of a protective CD8(+) T-cell response against infectious or malignant diseases are widely used in the clinic but, despite their success in animal models, they do not yet live up to their promise in humans. This review assesses the development of synthetic peptide vaccines, weighs it against the immunological concepts that have emerged, and identifies the key issues that play a role in the failure or success of a synthetic peptide vaccine. The current state-of-the-art peptide vaccine is a complete synthetic inflammatory product that is ingested by professional antigen-presenting cells and stimulates both CD4(+) and CD8(+) T cells.
Leiden University Medical Center, Department of Immunohematology, Leiden, The Netherlands. matijnbijker@yahoo.com
Martijn S
MS
Bijker
Cornelis J M
CJ
Melief
Rienk
R
Offringa
Sjoerd H
SH
van der Burg
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015195:Drug Design; D018984:Epitopes, T-Lymphocyte; D006801:Humans; D007108:Immune Tolerance; D010455:Peptides / Q000276:immunology* / Q000493:pharmacokinetics; D014614:Vaccines, Synthetic / Q000276:immunology*
D000276:Adjuvants, Immunologic; D018984:Epitopes, T-Lymphocyte; D010455:Peptides; D014614:Vaccines, Synthetic